Background and Aims: Infliximab (IFX) is one of the most potent and effective treatments for steroid- or immunomodulator-refractory ulcerative colitis (UC). We evaluated the early efficacy of IFX, based on endoscopic findings, and also attempted to define endoscopic findings predictive of IFX efficacy.
Saruta M, Komoike N, Arai Y, Ide D, Iwasaki T, et al. (2015) Endoscopic Findings during the Early Induction Phase of Infliximab Therapy may Predict its Efficacy for Refractory Ulcerative Colitis. J Gastrointest Dig Syst 5:324. doi:10.4172/2161-069X.1000324